Executive Summary
 

Dassault Systèmes acquisition of ArisGlobal follows an established industrial technology M&A playbook. Schneider Electric took full control of AVEVA for $10.8 billion (buying out the remaining 40% stake for $4.4 billion), Emerson acquired National Instruments for $8.2 billion and Rockwell Automation bought Plex Systems for $2.22 billion. In each case, the buyer offset slowing growth in a mature industrial technology market with a large transaction, using ownership to add recurring software revenue, strengthen cloud or data driven workflows and reduce dependence on slower growing core markets. This strategy differs from capability acquisitions designed to close a product gap or secure an early position in an emerging market: the primary objective is not incremental capability, but enough revenue scale and growth to reshape the parent company’s portfolio economics.
 

ArisGlobal fits this playbook: a scaled software platform with higher growth and regulated workflows that can alter 3DS’s revenue mix rather than simply add another product. This is a growth architecture acquisition, not merely continued expansion in life sciences. It will use balance sheet capacity to add recurring revenue, extend Medidata into safety and regulatory workflows and gain control over data rich workflows that would be difficult to replicate organically or secure through partnership.
 

The announced price is $1.8 billion in cash at closing and up to $200 million in additional consideration linked to multiyear AI related revenue milestones.
 

This transaction will be the second largest acquisition in 3DS’s history, behind its $5.8 billion purchase of Medidata Solutions in 2019. ArisGlobal’s LifeSphere platform supports pharmacovigilance, regulatory compliance and medical affairs across more than 300 life sciences organizations, including the US FDA. With $175 million in annual revenue and double-digit growth, the reported price implies a valuation of roughly 10x revenue on the cash considerations or ~11x including the earnout.
 

While strategic synergies are straighforward, the near-term financial rationale is equally important.

3DS revenue grew 4% at constant currencies in 2025, slowed to 3% in Q1 2026 and returned to 4% in Q2, while full-year total revenue guidance stands at 5-7% (with software revenue guided at 6-8%). The more pronounced weakness is based in Life Sciences, where software revenue declined 2% in 2025, 3% in Q1 and 4% in Q2, including a 3% decline at Medidata in the latest quarter.
 

ArisGlobal’s approximately $175 million in annual revenue would provide an immediate top line contribution and partially offset weaker organic momentum. The transaction could also be financed largely from 3DS’s €2.28 billion net financial position, limiting the need for equity issuance or substantial new debt. 3DS announced that the deal should be accretive to revenue growth and EPS in Year 1.